证券代码：600332 证券简称：白云山 广州白云山医药集团股份有限公司 投资者关系活动记录表 ■特定对象调研 £分析师会议 £媒体采访 £业绩说明会 投资者关系活 动类别 □新闻发布会路演活动 □现场参观 £其他 线上会议、现场调研 召开方式 时间 2023年9月19日至9月25日 地点 线上、公司 董事会秘书黄雪贞女士、证券事务代表黄瑞媚女士、董事会秘 公司参与人员 书室经理郭云倩女士 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023年9月25日，广州白云山医药集团股份有限公司（以下简称"本 公司"）全资子公司广州白云山中一药业有限公司（以下简称"中一药 业"）收到加拿大卫生部签发的产品注册证书。现将相关情况公告如下： 一、产品的基本情况 产品名称：加味藿香正气丸 证券代码：600332 证券简称：白云山 公告编号：2023－049 广州白云山医药集团股份有限公司 关于子公司收到加拿大产品注册证书的公告 品种批准文号（NPN）: 80126887 年加味藿香正气丸在国内城市零售药店的销售额为人民币 1,551 万元。截 至目前，中一药业在加味藿香正气研发项目上已投入研发费用合计约人 民币 500 万元（未审计）。 三、对本公司的影响及风险提示 剂型：丸剂 生产企业：（1）名称：广州白云山中一药业有限公司，（2）地址： 中国广东省广州市黄埔区云埔一路32号 申请单位: Topwin Trading Co.,Ltd.,11180 River Road,Unit 2140, Richmond,British ...

Financial Performance - The company reported no interim dividend distribution for the six months ending June 30, 2023[1]. - The financial report for the reporting period was prepared in accordance with Chinese accounting standards and is unaudited[2]. - The board of directors confirmed the accuracy and completeness of the financial report[1]. - The company's operating revenue for the reporting period reached RMB 39,970,331 thousand, representing a year-on-year increase of 7.39% compared to RMB 37,220,451 thousand in the same period last year[13]. - Net profit attributable to shareholders was RMB 2,811,248 thousand, an increase of 8.54% from RMB 2,589,996 thousand in the previous year[13]. - The net profit after deducting non-recurring gains and losses was RMB 2,598,509 thousand, reflecting a growth of 12.96% compared to RMB 2,300,375 thousand last year[13]. - The total profit for the same period was RMB 3,532,692 thousand, reflecting a year-on-year growth of 6.02%[37]. - Basic earnings per share rose to RMB 1.729, an increase of 8.54% from RMB 1.593 in the same period last year[13]. - The weighted average return on net assets was 8.40%, a slight decrease of 0.13 percentage points compared to 8.53% in the previous year[13]. - The company's net cash flow from operating activities decreased significantly to RMB (740,710) thousand, a decline of 143.26% from RMB 1,712,214 thousand in the previous year[13]. Risk Management - There are no significant risks that materially affect the company's production and operations during the reporting period[10]. - The financial report includes a section on potential risks that the company may face[10]. - The company has not faced any situation where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the semi-annual report[2]. - The company has established an online risk control supervision platform to improve risk warning standards and enhance risk identification accuracy[103]. - The company aims to strengthen internal control and risk management systems to ensure the achievement of strategic goals[100]. Corporate Governance - The company has fully complied with the corporate governance code as per the Hong Kong Stock Exchange regulations[100]. - In the first half of 2023, the company organized 1 shareholders' meeting, 6 board meetings, and 5 supervisory meetings[100]. - The company completed the re-election of the board and supervisory committee members in May 2023, appointing new executives and committee members[101]. - The company conducted a self-assessment of its internal control and social responsibility, resulting in the publication of the 2022 Internal Control Evaluation Report and the 2022 ESG Report[100]. Environmental Compliance - The company reported that its chemical pharmaceutical plant exceeded emission standards for several pollutants, including COD at 114.17 mg/L, which is above the standard of 500 mg/L[106]. - The company is committed to enhancing its environmental performance and reducing pollutant discharge through ongoing assessments and compliance measures[110]. - The company has multiple facilities with nitrogen oxides (NOx) emissions exceeding the regulatory limits, indicating a need for improved emission controls[108]. - The company has established a total of 12 pollution control facilities across various production lines, enhancing its environmental compliance efforts[114]. - The company has committed to continuous improvement in its environmental performance, aligning with national standards and regulations[112]. Market Position and Strategy - The company is a leader in the antibiotic market with a complete industrial chain from raw materials to formulations, aiming to establish a top brand in oral antibiotics[21]. - The company has 323 products included in the National Medical Insurance Catalog and 331 products in the provincial medical insurance catalog, indicating strong market presence[19]. - The company is expanding its medical services and healthcare investments, with projects like Baiyunshan Hospital and healthcare service companies[24]. - The company is focusing on innovation and high-end formulation production technology as part of the "14th Five-Year Plan"[25]. - The company is actively expanding its market presence and enhancing its product offerings through continuous research and development efforts[35]. Related Party Transactions - The total amount of related party transactions during the reporting period was 185,190,000 RMB, with various types of transactions including sales of goods and provision of services[154]. - The company reported a related party transaction amount of 76,352,000 RMB for sales of goods at market price[156]. - The company engaged in related party transactions with Baiyunshan Hehuang Company amounting to 85,305,000 RMB for sales of goods at market price[156]. - The company provided advertising agency services to Guangzhou Baiyunshan Cultural Industry Co., Ltd. for 134,000 RMB[156]. Investment and Capital Expenditure - The group plans to spend approximately RMB 2.677 billion on capital expenditures in 2023, with RMB 867 million already spent in the first half of the year[60]. - The company invested RMB 401 million in R&D during the first half of 2023, obtaining six production approvals for new drugs and one clinical trial approval[42]. - The company has confirmed that the accounting policy changes will not have a significant impact on its financial position, operating results, and cash flows for the current period[172]. - The company has utilized RMB 243.90 million of the raised funds in the first half of 2023, with a cumulative investment of RMB 7,130.35 million as of June 30, 2023[178]. Employee and Labor Relations - The total number of employees in the group as of the end of the reporting period is 23,493, with total employee wages amounting to approximately RMB 2.05 billion in the first half of 2023[194]. - The company has implemented a comprehensive training management system to promote employee development, covering all levels from frontline workers to senior management[196]. - The company emphasizes equal employment and respects diverse backgrounds, firmly opposing any form of discrimination[195]. Shareholder Information - As of June 30, 2023, the number of shareholders holding the company's stock was 91,239, with 91,188 holding A-shares and 51 holding H-shares[185]. - The top ten shareholders held a total of 732,305,103 shares, representing 45.04% of the total share capital[185]. - The largest shareholder, Guangyao Group, maintained its shareholding at 732,305,103 shares, with no changes during the reporting period[186].

证券代码：600332 证券简称：白云山 公告编号：2023－048 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 全资子公司广州白云山中一药业有限公司（以下简称"中一药业"） 收到广东省药品监督管理局核准签发的《药品生产许可证》，同意 中一药业接受广州白云山奇星药业有限公司（以下简称"奇星药业"） 委托生产蛇胆川贝散（国药准字 Z44020752）、喉康散（国药准字 Z44020781）。现将相关情况公告如下： 一、《药品生产许可证》基本情况 企业名称：广州白云山中一药业有限公司 许可证编号：粤 20160046 分类码：AhzxBzCz 注册地址：广州市黄埔区云埔一路 32 号 发证机关：广东省药品监督管理局 有效期至：2025 年 8 月 20 日 生产地址和生产范围： 二、药品生产许可证副本变更情况 同意中一药业接受奇星药业委托生产蛇胆川贝散（国药准字 Z44020752）、喉康散（国药 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2023年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 00874 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 | RMB | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 | RMB | | 1 RMB | | 219,900,000 | | 2. 股份分類 | 普通股 | 股份類別 | A | | ...

Financial Performance - The company's operating revenue for the current period reached RMB 39,970,331 thousand, representing a year-on-year increase of 7.39% compared to RMB 37,220,451 thousand in the same period last year[15]. - The net profit attributable to shareholders for the current period was RMB 2,811,248 thousand, an increase of 8.54% from RMB 2,589,996 thousand in the previous year[15]. - The net profit after deducting non-recurring gains and losses was RMB 2,598,509 thousand, reflecting a 12.96% increase from RMB 2,300,375 thousand in the same period last year[16]. - Total profit reached RMB 3,532,692 thousand, reflecting a growth of 6.02% compared to the previous year[35]. - The basic earnings per share for the current period were RMB 1.729, up 8.54% from RMB 1.593 in the same period last year[16]. - The total revenue for the group reached RMB 39,832,674 thousand, representing a year-on-year increase of 7.41%[42]. - The revenue from the health segment was RMB 7,047,787 thousand, with a year-on-year growth of 8.07%[42]. Cash Flow and Assets - The net cash flow from operating activities showed a significant decline, amounting to (RMB 740,710 thousand), a decrease of 143.26% compared to RMB 1,712,214 thousand in the previous year[16]. - The total assets at the end of the current period were RMB 73,607,239 thousand, a decrease of 1.42% from RMB 74,665,299 thousand at the end of the previous year[16]. - The cash and cash equivalents as of June 30, 2023, amounted to RMB 19,787,561 thousand, a decrease from RMB 20,804,699 thousand at the end of 2022[45]. - The company's bank borrowings increased to RMB 12,142,688 thousand, up 13.78% from RMB 10,675,850 thousand at the end of 2022[46]. - The total liabilities decreased to RMB 38.23 billion as of June 30, 2023, down from RMB 41.03 billion at the end of 2022, representing a reduction of 6.8%[163]. - The total current assets amounted to approximately RMB 53.82 billion, a decrease from RMB 57.06 billion at the end of 2022, reflecting a decline of about 5.5%[158]. Investments and R&D - R&D expenses amounted to RMB 400,574 thousand, a decrease of 9.23% from the previous year[39]. - The company invested RMB 3.34 billion in the establishment of the Guoyao Fund, enhancing its capital operation capabilities[39]. - The company is in the investment expansion phase of its large medical sector, focusing on medical services, traditional Chinese medicine health management, and modern elderly care[25]. - The company has a comprehensive technology innovation system with 5 national-level R&D institutions and 17 provincial-level technology centers[33]. - The company launched new products including mountain camellia-flavored herbal tea and Wang Xiaojiji mini cans, expanding its product lineup[36]. Corporate Governance and Compliance - The financial report for the reporting period was prepared in accordance with Chinese accounting standards and is unaudited[3]. - The board of directors confirmed the authenticity, accuracy, and completeness of the financial report[3]. - The company has adhered to the corporate governance code and continuously improved its governance structure and information disclosure practices[73]. - The audit committee consists of four independent non-executive directors, ensuring compliance with accounting principles and standards, with no objections raised regarding the accounting treatment methods adopted by the company[77]. - The company is committed to enhancing its internal control and risk management systems to support high-quality development[73]. Environmental Responsibility - The company has successfully maintained compliance with environmental standards, with no exceedance in the discharge of total VOCs, COD, and other pollutants across its facilities[82]. - The company has implemented various pollution control facilities to ensure emissions are within standards, including a wastewater treatment facility with a daily processing capacity of 3,895 cubic meters per hour[84]. - The company has established a VOCs treatment system with a capacity of 12,000 cubic meters per hour, focusing on benzene and non-methane total hydrocarbons[85]. - The company has adopted clean energy for boiler combustion and is using energy-efficient equipment to reduce carbon emissions[90]. - The company has engaged third-party monitoring agencies to ensure compliance with environmental regulations[87]. Related Party Transactions - The total amount of related party transactions for the reporting period was RMB 258,917,000, with various transactions categorized under purchasing goods, providing services, and asset leasing[107]. - The company has maintained a consistent pricing principle based on market prices for its related party transactions[107]. - The non-operating fund occupation by controlling shareholders and related parties amounted to RMB 218.77 million, with a repayment of RMB 173.37 million during the reporting period[103]. - The remaining balance of non-operating fund occupation at the end of the reporting period was RMB 45.40 million, accounting for 0.13% of the latest audited net assets[103]. Market Position and Strategy - The core brand "Wanglaoji" has ranked first in the Chinese Brand Power Index for herbal tea for seven consecutive years, maintaining its leading position in the herbal tea industry[28]. - The company is leveraging digital and intelligent technologies to create new development opportunities in the pharmaceutical industry[26]. - The company has a strong marketing network with long-term partnerships with over tens of thousands of clients across more than 30 provinces, cities, and autonomous regions[32]. - The company is focused on expanding its health management and investment in the health industry[188]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[163].

香港交易及結算所有限公司及香港聯合交易所有限公司對本摘要的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本摘要全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2023年半年度報告摘要 一、 重要提示 1.1 本公司半年度報告摘要摘自本公司截至2023年6月30日止六個月的2023年半年度報告全 文，投資者欲瞭解詳細內容，應當仔細閱讀將刊載於上交所網站（http://www.sse.com.cn） 等中國證監會指定網站和港交所網站（http://www.hkex.com.hk）上的半年度報告全文。 1.2 本公司董事會、監事會及其董事、監事、高級管理人員保證本摘要內容的真實、準確、完 整，不存在虛假記載、誤導性陳述或者重大遺漏，並承擔個別和連帶的法律責任。 1.3 本公司董事出席了第九屆董事會第三次會議，其中，獨立非執行董事陳亞進先生因公務未 能親自出席本次董事會會議，委託獨立非執行董事黃民先生代為出席並行使表決權；執行 董事劉菊妍女士、獨立非執行董事黃龍德先生和孫寶清女士以通訊方式參加了 ...

证券代码：600332 证券简称：白云山 公告编号：2023—046 广州白云山医药集团股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次会计政策变更概述 广州白云山医药集团股份有限公司（以下简称"本公司"或"公司"）于 2023 年 8 月 18 日召开 2023 年第 6 次审核委员会会议，审议通过了《关于 2023 年半 年度财务报告中补充重要会计政策的议案》，该议案无需提交本公司董事会、 监事会和股东大会审议。本次会计政策变更，是依据财政部于 2022 年 11 月 30 日发布的《企业会计准则解释第 16 号》（财会〔2022〕31 号）（以下简称"解 释第 16 号"）对公司的会计政策进行变更。 二、具体情况及对公司的影响 （一）本次会计政策变更原因 2022 年 11 月 30 日，财政部发布了解释第 16 号，其中"关于单项交易产 生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理"的规定自 2023 年 1 月 1 日起施行。 （二）变更日期 ...

证券代码：600332 证券简称：白云山 公告编号：2023-045 广州白云山医药集团股份有限公司 第九届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"本公司"）第九届监事会第二 次会议（"会议"）于 2023 年 8 月 7 日以书面及电邮方式发出通知，会议 于 2023 年 8 月 18 日（星期五）在本公司所在地中国广东省广州市荔湾区 沙面北街 45 号公司会议室召开。本次会议应到监事 3 人，实到监事 3 人， 监事会主席蔡锐育先生主持了会议，会议的召集、召开符合《公司法》及 《公司章程》的规定。 经与会监事审议、表决，会议审议通过了如下议案： 一、本公司 2023 年半年度报告及其摘要 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票，审议通过本议案。 二、本公司 2023 年半年度财务报告 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票，审议通过本议案。 三、对本公司 2023 年半年度报告的书面审核意见 表决结果：同意票 3 票，反 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）发布的 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 以及《上海证券交易所上市公司自律监管指南第 1 号——公告格式》的 相关规定，广州白云山医药集团股份有限公司（以下简称"本公司"、 "公司"或"白云山"）就 2023 年半年度募集资金存放与实际使用情 况专项说明如下： 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额及资金到账时间 证券代码：600332 证券简称：白云山 公告编号：2023－047 广州白云山医药集团股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的专项报告 根据本公司第六届董事会第八次会议及第六届董事会第十三次会议 决议，经中国证监会出具的《关于核准广州白云山医药集团股份有限公 司非公开发行股票的批复》（证监许可【2016】826 号）核准，本公司 非公开发行人民币普通股 334,711, ...